Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 18/20 | 0.53 |
| ▸ | TNKS | O95271 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063134 | 0.88 | CHRM2 (0.64) | CALCRLTNKSPARP1PARP2CHRM2 | |
| SCHEMBL829117 | 0.84 | CALCRL (0.59) | CALCRLTNKSPARP1PARP2CHRM2 | |
| SCHEMBL2100682 | 0.81 | CALCRL (0.63) | CALCRLTNKSPARP1PARP2 | |
| SCHEMBL6580100 | 0.81 | CHRM2 (0.58) | CALCRLCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL1197774 | 0.81 | CALCRL (0.55) | CALCRL | |
| SCHEMBL31192594 | 0.81 | CALCRL (0.55) | CALCRL | |
| SCHEMBL12087688 | 0.80 | CALCRL (0.61) | CALCRLTNKSPARP1PARP2 | |
| SCHEMBL13074126 | 0.80 | CALCRL (0.59) | CALCRLTNKSPARP1PARP2 | |
| SCHEMBL1198682 | 0.80 | CALCRL (0.59) | CALCRLTNKSPARP1PARP2 | |
| SCHEMBL3956625 | 0.79 | CALCRL (0.63) | CALCRLTNKSPARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176986-A1 | Process for the Preparation of Pyridine Heterocycle Cgrp Antagonist Intermediate | MERCK SHARP & DOHME CORP. | 2009-07-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176986-A1 | Process for the Preparation of Pyridine Heterocycle Cgrp Antagonist Intermediate | CCKBR, CALCRL, CALCR | CALCRL 2/4885TNKS 970/4885PARP1 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.